Cover Image

Evaluation of Piperacillin/Sulbactam, Piperacillin/Tazobactam and Cefoperazone/Sulbactam Dosages in Gram-Negative Bacterial Bloodstream Infections by Monte Carlo Simulation

The optimal regimens of piperacillin/sulbactam (PIS 2:1), piperacillin/tazobactam (PTZ 8:1), and cefoperazone/sulbactam (CSL 2:1) are not well defined in patients based on renal function. This study was conducted to identify optimal regimens of BLBLIs in these patients. The antimicrobial sensitivity...

Full description

Saved in:

Bibliographic Details
Main Authors:	Xueting Wang (Author), Luying Xiong (Author), Wei Yu (Author), Chen Huang (Author), Jinru Ji (Author), Chaoqun Ying (Author), Zhiying Liu (Author), Yunbo Chen (Author), Yonghong Xiao (Author)
Format:	Book
Published:	MDPI AG, 2023-02-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Activity Of Piperacillin/Tazobactam And Cefoperazone/Sulbactam Against Pathogenic Isolates Of Enterobacteriaceae
by: Qamar un nisa Naz, et al.
Published: (2024)

Synergistic Activity of Cefiderocol in Combination with Piperacillin-Tazobactam, Fosfomycin, Ampicillin-Sulbactam, Imipenem-Relebactam and Ceftazidime-Avibactam against Carbapenem-Resistant Gram-Negative Bacteria
by: Marta Palombo, et al.
Published: (2023)

Hypersensitivity vasculitis induced by cefoperazone/sulbactam
by: Ariturk Ender, et al.
Published: (2003)

In Vitro Antimicrobial Activity of Various Cefoperazone/Sulbactam Products
by: Ming-Jen Sheu, et al.
Published: (2020)

Piperacillin/Tazobactam (ZOSYN)
by: Stephanie M. Culver, et al.
Published: (1996)

Hemolytic Anemia and Reactive Thrombocytosis Associated With Cefoperazone/Sulbactam
by: Ling Zhou, et al.
Published: (2019)

Mechanisms of Piperacillin/Tazobactam Nephrotoxicity: Piperacillin/Tazobactam-Induced Direct Tubular Damage in Mice
by: Jihyun Yang, et al.
Published: (2023)

Acute localized exanthematous pustulosis caused by cefoperazone and sodium sulbactam
by: Yan-Jing Qu, et al.
Published: (2016)

Comparing the Outcomes of Cefoperazone/Sulbactam-Based and Non-Cefoperazone/Sulbactam-Based Therapeutic Regimens in Patients with Multiresistant <i>Acinetobacter baumannii</i> Infections-A Meta-Analysis
by: Chienhsiu Huang, et al.
Published: (2024)

Optimal Dose of Cefoperazone-Sulbactam for Acute Bacterial Infection in Patients with Chronic Kidney Disease
by: Chien-Ming Chao, et al.
Published: (2022)

CLINICAL AND PHARMACOECONOMICAL EFFICIENCY OF CEFOPERAZONE + SULBACTAM IN CHILDREN, SUFFERING FROM CYSTIC FIBROSIS
by: E.B. Pavlinova, et al.
Published: (2006)

CLINICAL AND PHARMACOECONOMICAL EFFICIENCY OF CEFOPERAZONE + SULBACTAM IN CHILDREN, SUFFERING FROM CYSTIC FIBROSIS
by: E.B. Pavlinova, et al.
Published: (2006)

The role of piperacillin/tazobactam in the treatment of Hidradenitis suppurativa
by: Aviv Barzilai, et al.
Published: (2024)

Pharmacokinetics of Piperacillin-Tazobactam in Critically Ill Patients with Open Abdomen and Vacuum-Assisted Wound Closure: Dosing Considerations Using Monte Carlo Simulation
by: Cédric Carrié, et al.
Published: (2024)

Piperacillin/tazobactam treatment in children: evidence of subtherapeutic concentrations
by: Panpan Ye, et al.
Published: (2024)

Piperacillin/Tazobactam as Cause of Acute Generalized Exanthematous Pustulosis
by: Aikaterini Kyriakou, et al.
Published: (2019)

Evaluation of Strategies for Reducing Vancomycin-Piperacillin/Tazobactam Incompatibility
by: Anthony Martin Mena, et al.
Published: (2023)

Clinical Outcomes and Adverse Effects in Septic Patients with Impaired Renal Function Who Received Different Dosages of Cefoperazone-Sulbactam
by: Chien-Hsiang Tai, et al.
Published: (2022)

Risk-factor analysis and predictive-model development of acute kidney injury in inpatients administered cefoperazone-sulbactam sodium and mezlocillin-sulbactam sodium: a single-center retrospective study
by: Ruiqiu Zhang, et al.
Published: (2023)

Efficacy of Cefoperazone Sulbactam in Patients with <i>Acinetobacter</i> Infections: A Systematic Review of the Literature
by: Gowthami Sai Kogilathota Jagirdhar, et al.
Published: (2023)

The use of Pharmacokinetic and Pharmacodynamics to evaluate The recommended dosing regimens of Cefoperazone-Sulbactam in patients with hospital-Acquired Pneumonia
by: Narawadee Niamhun
Published: (2014)

Piperacilina/tazobactam en el sistema VITEK ®2 Piperacillin / Tazobactam in the VITEk ®2 System
by: Javier Gutman, et al.
Published: (2011)

The impact of a best practice advisory on inpatient prescribing of piperacillin-tazobactam
by: Katherine L. Peterson, et al.
Published: (2022)

Incidence and Determinants of Piperacillin/Tazobactam-Associated Hypokalemia: A Retrospective Study
by: Heenam Seo, et al.
Published: (2022)

Comparison of Cefepime with Piperacillin/Tazobactam Treatment in Patients with Hospital-Acquired Pneumonia
by: Bo-Guen Kim, et al.
Published: (2023)

Comparison of Piperacillin and Tazobactam Pharmacokinetics in Critically Ill Patients with Trauma or with Burn
by: Daniel J. Selig, et al.
Published: (2022)

Simple HPLC-UV Method for Piperacillin/Tazobactam Assay in Human Plasma
by: Khaled Abdelkawy, et al.
Published: (2023)

Synthesis and evaluation of polymeric micelle containing piperacillin/tazobactam for enhanced antibacterial activity
by: Milani Morteza, et al.
Published: (2019)

Clinical effectiveness of branded versus generic piperacillin-tazobactam for treating severe community-acquired pneumonia
by: Cheng-Yi Wang, et al.
Published: (2022)

Re-evaluation of cefepime or piperacillin-tazobactam to decrease use of carbapenems in extended-spectrum beta-lactamase-producing Enterobacterales bloodstream infections (REDUCE-BSI)
by: Catherine H. Vu, et al.
Published: (2022)

Piperacillin-Tazobactam as an Adjuvant in the Mechanical Treatment of Patients with Periodontitis: A Randomized Clinical Study
by: Dolores Hurtado-Celotti, et al.
Published: (2022)

Electrolyte Disorders Associated with Piperacillin/Tazobactam: A Pharmacovigilance Study Using the FAERS Database
by: Heenam Seo, et al.
Published: (2023)

Acute Kidney Injury in Pediatric Treated with Vancomycin and Piperacillin-Tazobactam in Tertiary Care Hospital
by: Mohammed Al Nuhait, et al.
Published: (2018)

Evaluation of Piperacillin/Tazobactam Use and Resistance Pattern in a Teaching Hospital, Northwest Iran
by: Afshin Shiva, et al.
Published: (2022)

Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative Infections
by: Pasquale Maria Berrino, et al.
Published: (2023)

Bloodstream Infection due to Piperacillin/Tazobactam Non-Susceptible, Cephalosporin-Susceptible <i>Escherichia coli</i>: A Missed Opportunity for De-Escalation of Therapy
by: Leah Carlisle, et al.
Published: (2018)

Comparison of bleeding risk and hypofibrinogenemia-associated risk factors between tigecycline with cefoperazone/sulbactam therapy and other tigecycline-based combination therapies
by: Lei Zhang, et al.
Published: (2023)

Penetration of Piperacillin/Tazobactam Into Gynecologic Tissues Following a Single Loading Dose Prior to Hysterectomy
by: William F. O'Brien, et al.
Published: (1994)

Pilot study evaluating intravenous amoxicillin-clavulanate as an alternative to piperacillin-tazobactam for general surgery patients
by: Sarah A. Drost, et al.
Published: (2023)

Superinfection rate among the patients treated with carbapenem versus piperacillin/tazobactam: Retrospective observational study
by: Hessa Al Muqati, et al.
Published: (2021)